-
Japan's Ministry of Health, Labour and Welfare approves Vadadustat for anemia caused by chronic kidney disease
Time of Update: 2020-07-12
Biopharmaceutical company Akebia Therapeutics announced today that Japan's Ministry of Health, Labour and Welfare has approved the hypoxic-induced factor oxalate oxytoxe inhibitor vadadustat for the
-
Nature: What are the different rates of blood cancer in different populations?
Time of Update: 2020-07-12
At present, it is not clear to what extent the biology of tumor occurrence and aging is shaped by differences in human populations As you age, hematopoietic cloning with acquired mutations becomes c
-
Collection: Blood Research Selected on June 25, 2020
Time of Update: 2020-07-12
1 The primary cell-like chronic myeloid leukemia model based on genetic heterogeneity BCR-ABL1 kinase targeted therapy revolutionized the treatment of chronic stage (CP) chronic myeloid leukemia
-
WFH 2020: Four-year data show that type A haemophilia gene therapy valoctocogene roxaparvovec can continue to reduce bleeding
Time of Update: 2020-07-12
BioMarin, a pharmaceutical company, recently released the results of an ongoing Phase I/II trial, which for four years showed a significant reduction in bleeding rates and improved levels of factor
-
Blood: Promoting red blood cell production joint iron restriction seislus significantly improved anemia of beta-thalassemia
Time of Update: 2020-07-12
Moderate thalassemia is a disease characterized by red blood cell production ineffective (IE), anemia, spleen enlargement, and systemic iron overload Researchers are exploring new treatments based o
-
Brit J Heamatol: Clinical Outcome of T-Cell Large Particle Lymphocytic Leukemia
Time of Update: 2020-07-12
T-cell large granulele leukemia (T-LGLL) is an incurable form of leukemia characterized by abnormal cytotoxic T-cell cloning proliferation, which can lead to severe neutrophil reduction, blood trans
-
Once a week, subcutaneous injection of C5 supplement inhibitor ULTOMIRIS, treatment of burst sleep-based hemoglobinuria reached the clinical endpoint of Stage III
Time of Update: 2020-07-12
Alexion Pharmaceuticals announced that its weekly patient self-inderite injection ULTOMIRIS treatment of bisonal hemoglobinuria (PNH) has reached the primary end of the trial On the 71st day, subcut
-
Blood: A new red blood cell production regulation mode
Time of Update: 2020-07-12
Eryteonin (Epo) provides the primary survival signal for mature erythropoietin (EPs) and is essential for end-of-life erythropoietin production Still, progenitor cells can irreversibly differentiate
-
Blood: The molecular mechanism of RUNX1 methylation disorder induced leukemia
Time of Update: 2020-07-12
RUNX1 is the most common mutant gene in human leukemia, and loss or dominant negative inhibition of RUNX1 function is found in myelogenic hyperplasia syndrome and acute myeloid leukemia (AML) Howeve
-
Blood: Lysine-specific demethylatase 1A (LSD1) limits in vitro amplification of human HSC and is a target for UM171
Time of Update: 2020-07-12
At present, hematopoietic stem cells transplantation is still the only cure for a variety of malignant blood diseases, but has been limited by the lack of cell donors, high-quality cells can not f
-
Brukinsa, a BTK inhibitor in Baiji Shenzhou, is under review in Europe for the treatment of Fahrenheit polycyloproteinemia
Time of Update: 2020-07-12
Brukinsa (zanubrutinib, Zebtinib), a BTK small molecule inhibitor developed by Baiji Shenzhou, has been censored by European regulators to treat patients with Fahrenheit polycyteproteinemia (WM)
-
Brit J Heamatol: Serum BDNF concentration seisprediction of multiple neuropathy and total survival in patients with multiple myeloma
Time of Update: 2020-07-12
Brain-derived neurotrophic factor (BDNF) is a protein that has multiple effects on neurons and vascular function However, its prognosis and function in multiple myeloma (MM) are still unknown , r
-
EU approves first red blood cell maturant Reblozyl to treat blood transfusion-dependent anemia
Time of Update: 2020-07-12
The European Commission has approved The BMS's Reblozyl (luspatercept) for the treatment of blood transfusion-dependent anemia associated with marrow hyperplasia syndrome (MDS) or beta thalassemia T
-
Blood: The new alternative to the ditric ludes, acute grafts for host disease!
Time of Update: 2020-07-12
Acute Transplant Anti-Host Disease (GVHD) is a life-threatening complication of allo-HCT The current GVHD treatment is primarily a immune system that targets the donor, and a recent study in the j
-
NEJM: Study on differences in the therapeutic dose of hydroxylurea in sickle cell anemia
Time of Update: 2020-07-12
Hydroxyurea has been shown to be highly safe, feasible and effective in children's sickle cell anemia in sub-Saharan Africa, reducing the incidence and mortality of vascular occlusion However, t
-
Concerned about the rare disease "true red blood cell hypertrophy" :P TG-300 approved by FDA orphan drug
Time of Update: 2020-07-12
True erythropoietin (polycythemia vera, PV) is a bone marrow proliferation tumor, a group of malignant tumors derived from hematopoietic stem cells , characterized by the proliferation of bone marr
-
Blood: Arginine synthesis "buff" enhances the proliferation and anti-tumor efficacy of CAR-T cells
Time of Update: 2020-07-12
Blood and solid tumors break down the metabolism of the semi-essential amino acid arginine to drive cell proliferation, resulting in lower arginine levels in the tumor microenvironment The low argin
-
Blood: RGS10 and RGS18 work together to limit unnecessary platelet activation
Time of Update: 2020-07-12
G protein conjugate receptor sishose activation is a key medium, and its signaling can be regulated by members of the G protein signal (RGS) family regulator The two most abundant RGS proteins in hu
-
Blood: The Structural Foundation of PAR4 Activation and Its Role in VTE
Time of Update: 2020-07-12
Protease activation receptor 4 (PAR4) mediates the continuous signalconductofing of clotting enzymes in platelets, which is necessary to stabilize blood clots PAR4 is activated by protein hydrolys
-
Experts suggest building a three-dimensional AIDS security system
Time of Update: 2020-07-12
AIDS as an important public health issue, irreversible and hidden transmission methods make it a threat to public health Cai Weiping, director of the Infection center of the Eighth People's Hospit
